LA CHAUX-DE-FONDS, Switzerland and PARAMUS, N.J., March 6, 2018 /PRNewswire/ -- Glenmark
"The Biopôle is one of the most vibrant ecosystems for life sciences innovation in Europe. This expansion opens a universe of opportunity to foster our innovation capabilities by collaborating with the world class research centres, academic groups and hospitals in the Lausanne vicinity. At the same time, Glenmark's long-term commitment to our development centre in the region of Neuch?tel will remain a key priority," said Dr. Kurt Stoeckli, President and Chief Scientific Officer of Glenmark Pharmaceuticals.
The company's rapidly evolving pipeline of novel biologics and the growing demand for technical development and manufacturing will require further expansion of current capabilities and capacities. Glenmark will continue to evaluate expansions and enhancements to accommodate the increasing demand for biologics development and manufacturing in the canton of Neuch?tel.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd. (GPL) is a global innovative pharmaceutical company with operations in more than 50 countries. Glenmark has a diverse pipeline with several compounds in various stages of clinical development, primarily focused in the areas of oncology, respiratory disease and dermatology. Glenmark has improved the lives of millions of patients by offering safe, affordable medications for nearly 40 years. For more information, visit glenmarkpharma-us.com.
Glenmark Pharmaceuticals S.A., established in Switzerland in 2004, is a research and development centre focused on biologics. It is a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd. of India. Glenmark's biologics research centre has a robust pipeline of monoclonal antibodies in various stages of development, including bispecific antibodies. The focus of the biologics research and development centre is to develop novel biologic entities in the therapeutic areas of immunology, oncology and inflammation. Glenmark S.A. currently employs approximately 160 people at its research centre.
View original content:http://www.prnewswire.com/news-releases/glenmark-pharmaceutical-sa-to-invest-in-new-translational-research-group-at-biopole-lausanne-epalinges-300608478.html
SOURCE Glenmark Pharmaceuticals
Subscribe to our Free Newsletters!
Ear, nose and throat are important organs and disease in one area can affect the others. ENT ...
If you want to stop breastfeeding, then here is your guide to doing it the right way. Find the ...
Botulism is a rare but potentially lethal illness caused by botulinum neurotoxin released by the ...View All